TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
The renal and biliary stent market benefits from an aging population, rising incidence of urolithiasis and biliary diseases, and expanding minimally invasive procedures. Technological advances such as drug‑eluting stents and bio‑resorbable materials are driving higher adoption rates.
While North America retains the largest share due to robust reimbursement frameworks, the Asia‑Pacific region is emerging rapidly thanks to increased healthcare spending and growing awareness of endoscopic interventions.
Looking forward, manufacturers are likely to focus on product differentiation, strategic collaborations, and geographic expansion to capture the projected 7.4% CAGR through 2034.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast perio
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
The global Renal and Biliary Stent System market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.0 billion by 2034, at a CAGR of 7.5% during the forecast period.
Renal and Biliary Stent Systems are medical devices designed to keep the renal (kidney) and biliary (bile duct) passages open, addressing obstructions caused by stones, tumors, strictures or inflammatory conditions. The U.S. market size is estimated at USD 300 million in 2025, while China is expected to reach USD 200 million. The Self‑Expanding Stents segment is anticipated to achieve USD 600 million by 2034, driven by an estimated 8.0% CAGR over the next six years. Leading manufacturers include Abbott, Boston Scientific, Medtronic, BD, Taewoong Medical (Olympus), Cook Medical, Merit Medical Systems, Nano Therapeutics, Meril Life, and ELLA‑CS, with the top five players accounting for roughly 45% of total revenues in 2025.
Self‑Expanding Stents Lead the Market Due to Superior Conformability and Reduced Migration
The market is segmented based on type into:
Self‑Expanding Stents
Subtypes: Nitinol alloy, Polymer‑based, Hybrid designs
Balloon‑Expandable Stents
Subtypes: Stainless steel, Cobalt‑chromium
Unmounted (Bare) Stents
Ureteral Obstruction Segment Dominates Due to Rising Incidence of Kidney Stones and Malignancies
The market is segmented based on application into:
Ureteral Obstruction
Biliary Obstruction
Hospitals Remain the Primary End‑User, Supported by Growing Interventional Radiology Programs
The market is segmented based on end user into:
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global Renal and Biliary Stent System market was valued at approximately US$3.2 billion in 2025 and is projected to reach US$5.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.6 % over the forecast horizon. These stents—designed to keep renal and biliary passages open—address obstructions caused by tumors, stones, or strictures, and their demand is driven by rising incidence of urological and hepatobiliary disorders worldwide.
In the United States, the market size is estimated at US$1.0 billion for 2025, while China is forecast to achieve US$0.9 billion the same year, reflecting strong adoption of minimally invasive therapies in both regions. The self‑expanding stents segment alone is expected to reach US$1.2 billion by 2034, posting a 6.3 % CAGR during the next six years, as clinicians favor its flexibility and reduced restenosis rates.
The competitive landscape is semi‑consolidated, with a mix of large multinational corporations and specialized midsize firms. Abbott Laboratories leads the market owing to its broad portfolio of drug‑eluting renal stents and strategic partnerships across North America and Europe. Boston Scientific and Medtronic command significant shares thanks to their innovative balloon‑expandable and self‑expanding platforms, which are increasingly used in complex biliary interventions.
Meanwhile, BD (Becton, Dickinson and Company) and Taewoong Medical (Olympus) have accelerated growth through geographic expansion in Asia‑Pacific, targeting emerging hospital networks. Cook Medical, Merit Medical Systems, and Nano Therapeutics are bolstering their pipelines with next‑generation bio‑resorbable stents, aiming to capture the projected 45 % revenue share held by the top five players in 2025.
Abbott Laboratories
Boston Scientific
Medtronic
BD (Becton, Dickinson and Company)
Taewoong Medical (Olympus)
Cook Medical
Merit Medical Systems
Nano Therapeutics
Meril Life Sciences
ELLA‑CS
Blueneem Medical Devices
Sahajanand Medical Technologies
M.I. TECH
S&G Biotech
Micro‑Tech
The global Renal and Biliary Stent System market was valued at US$4.5 billion in 2025 and is projected to reach US$7.9 billion by 2034, at a CAGR of 5.2% during the forecast period. These devices, essential for maintaining patency in the renal and biliary tracts, have benefited from rising incidence of urolithiasis, cholangiocarcinoma, and benign strictures, which together account for an estimated 1.3 million new cases annually worldwide. The United States, the largest single‑country market, is estimated at US$1.2 billion in 2025, while China is expected to reach US$600 million the same year. The surge in outpatient endoscopic procedures, coupled with reimbursement reforms that favor minimally invasive solutions, has accelerated adoption across both mature and emerging economies.
Technological Innovation
Self‑expanding stents, favored for their conformability in tortuous ureteral and biliary anatomy, are poised to dominate the segment, with revenues projected to hit US$2.5 billion by 2034 and an anticipated 6.1% CAGR over the next six years. Balloon‑expandable stents retain niche relevance in high‑flow biliary applications, while unmounted stents are gaining traction through cost‑effective packaging for emerging markets. Companies such as Abbott, Boston Scientific, and Medtronic are intensifying R&D pipelines to integrate bio‑resorbable polymers and drug‑eluting coatings, aiming to reduce restenosis rates that currently affect roughly 12% of implanted devices within the first year. The convergence of imaging advances—especially intraductal ultrasound and real‑time fluoroscopy—with smart deployment systems is further enhancing procedural precision.
Regulatory pathways in North America and the European Union have become more streamlined, with recent FDA guidance allowing expedited review for next‑generation stents that demonstrate superior clinical outcomes in controlled trials. In parallel, the Asian market is witnessing accelerated approvals, driven by national health initiatives in China and Japan that prioritize early detection of biliary cancers. The global key manufacturers—including Abbott, Boston Scientific, Medtronic, BD, Taewoong Medical (Olympus), Cook Medical, Merit Medical Systems, Nano Therapeutics, Meril Life, and ELLA‑CS—collectively commanded approximately 45% of total market revenue in 2025. Competitive intelligence gathered from manufacturers, distributors, and clinical experts highlights a focus on strategic collaborations, such as co‑development agreements with imaging firms, and expansion of manufacturing capacity in low‑cost regions to meet rising demand while preserving margin stability.
North America currently holds the largest share of the global Renal and Biliary Stent System market, driven by a mature healthcare infrastructure, high per‑capita spending on advanced procedures, and strong reimbursement frameworks in the United States and Canada. The United States alone accounted for roughly 45 % of global revenue in 2025, with a market size estimated at USD 600 million. Robust adoption of minimally invasive urology and endoscopic biliary interventions, combined with the presence of leading manufacturers such as Abbott, Boston Scientific, and Medtronic, reinforces the region’s leadership. Canada contributes additional growth through public‑funded programs that increasingly favour self‑expanding stent technologies for ureteral obstruction.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region over the forecast period, primarily because of rapid urbanization, expanding middle‑class populations, and increasing prevalence of kidney stones and biliary diseases. China’s market is expected to reach USD 350 million by 2025, while Japan, South Korea, and India are experiencing double‑digit growth rates in stent adoption. Government‑backed initiatives to modernize hospital infrastructure and to increase access to endoscopic procedures are accelerating demand for both self‑expanding and balloon‑expandable stents. The region’s CAGR is estimated at 7.2 %, outpacing the global average.
Key Highlights:
How is healthcare policy and an aging population influencing regional demand for Renal and Biliary Stent Systems?
Across all regions, evolving healthcare policies that prioritize early diagnosis and minimally invasive treatment of renal and biliary conditions are expanding the addressable market. In Europe, the European Union’s “Europe’s Beating Cancer Plan” emphasizes timely intervention for biliary malignancies, boosting demand for high‑performance biliary stents. Meanwhile, North America’s Medicare updates have broadened coverage for outpatient ureteral stenting, encouraging outpatient procedures and reducing hospital stays. The aging demographics in both Europe and Japan increase the prevalence of chronic kidney disease, translating into higher procedural volumes for ureteral and percutaneous nephrostomy stents.
Key Highlights:
Key investment hubs include the United States, China, Germany, Japan, and the United Arab Emirates. The United States continues to attract venture capital for next‑generation bio‑resorbable stents, while Chinese firms are scaling domestic production to meet both local and export demand. Germany’s strong engineering base and regulatory reputation make it a preferred location for European R&D centers. Japan’s emphasis on precision manufacturing aligns with the development of ultra‑low profile stents for complex anatomy. The UAE is leveraging its strategic logistics position to become a distribution hub for the Middle East and Africa.
Minimally invasive surgery (MIS) initiatives are reshaping the treatment landscape for renal and biliary obstructions. In Europe, the adoption of robotic‑assisted ureteroscopy has driven up demand for low‑profile, high‑flexibility stents that can navigate tortuous anatomy. North America’s emphasis on outpatient urology clinics accelerates the uptake of bio‑resorbable stents that reduce the need for follow‑up removals. In the Asia‑Pacific, large‑scale hospital modernization programs—such as India’s “Ayushman Bharat” scheme—are equipping regional centers with state‑of‑the‑art endoscopy suites, thereby expanding the procedural base for both ureteral and biliary stenting. These modernization efforts are complemented by strategic procurement policies that favor devices with proven clinical outcomes and cost‑effectiveness.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Abbott, Boston Scientific, Medtronic, BD, Taewoong Medical (Olympus), Cook Medical, Merit Medical Systems, Nano Therapeutics, Meril Life, ELLA‑CS, among others.
-> Key growth drivers include rising incidence of urolithiasis and biliary cancers, increasing minimally invasive procedures, aging population, and expanding reimbursement frameworks.
-> North America holds the largest share, driven by high adoption of advanced stent technologies, while Asia‑Pacific is the fastest‑growing region.
-> Emerging trends include bio‑absorbable stents, drug‑eluting platforms, integration of AI‑guided imaging for precise deployment, and sustainability‑focused manufacturing processes.
